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Background: Atherosclerotic cardiovascular disease (CVD) is the most common cause of morbidity and mortality
among hemodialysis (HD) patients. It has been attributed, among other causes, to hypertension and dyslipidemia.
The aim of the present study was to investigate the effect of a year-long consumption of Pomegranate juice (PJ),
on two traditional cardiovascular (CV) risk factors: hypertension and lipid profile, as well as on cardiovascular events.
Methods: 101 HD patients were randomized to receive 100 cc of PJ (0.7 mM polyphenols) or matching placebo
juice, three times a week for one year. The primary endpoints were traditional CV risk factors; blood pressure and
lipid profile. Systolic, diastolic and pulse pressure, plasma levels of triglycerides (TG), high density lipoprotein (HDL),
low density lipoprotein (LDL) and total cholesterol were monitored quarterly during the study year. Secondary
endpoint was incidence of cardiovascular events.
Results: PJ consumption yielded a significant time response improvement in systolic blood pressure, pulse
pressure, triglycerides and HDL level; an improvement that was not observed in the placebo intake group. These
beneficial outcomes were more pronounced among patients with hypertension, high level of triglycerides and low
levels of HDL.
Conclusion: Regular PJ consumption by HD patients reduced systolic blood pressure and improved lipid profile.
These favorable changes may reduce the accelerated atherosclerosis and high incidence of CVD among HD
patients.
Trial registration: ClinicalTrials.gov registry, Identifier number: NCT00727519
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Patients on renal replacement therapy (RRT) are at in-
creased risk of cardiovascular (CV) mortality and morbid-
ity compared to the general population [1]. Every year,
between 10-20% of all patients on dialysis die, with about
45% of deaths attributed to CV causes [2]. Established
‘traditional’ atherosclerosis risk factors, such as hyperten-
sion and dyslipidemia, have been recognized as independ-
ent predictors of cardiovascular disease (CVD) among
chronic kidney disease (CKD) [1] and hemodialysis (HD)* Correspondence: liora.ore@gmail.com
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distribution, and reproduction in any mediumpatients [3,4]. Blood pressure is commonly high in HD pa-
tients. This phenomenon has been attributed to several
causes, among them the chronic volume overload in HD
patients, due to impaired blood pressure homoeostasis
function [4]. In addition to the high prevalence of hyper-
tension, HD patients usually display elevated triglycerides
(TG), reduced high density lipoprotein (HDL) cholesterol
and elevated concentration of lipoprotein-a [3,5], while
total and low density lipoprotein (LDL) cholesterol usually
remain within normal limits [5,6]. Several clinical trials
and meta-analyses have shown the cardiovascular benefits
of lowering blood pressure in patients with kidney diseasentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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cular benefits of improving lipid profile among dialysis pa-
tients is controversial [9], there is evidence that treatment
of HD patients with lipid lowering drugs is associated with
reduced CV mortality [10]. Therefore, improving lipid
profile and reduction of blood pressure is a therapeutic
target for patients on chronic dialysis.
It has been known for many years that high intake of
fruits and vegetables is associated with reduced risk of
coronary heart disease [11]. The beneficial effect of
fruits and vegetables may be related especially to flavo-
noids, which are thought to exert their action by inhi-
biting LDL oxidation and platelet aggregation [12], as
well as to inhibit the angiotensin converting enzyme
(ACE), a key component in the renin angiotensin aldos-
terone system (RAAS) which regulates blood pressure
[13]. Pomegranate juice (PJ) is a rich source of flavo-
noids and as such it has potent antioxidant activity.
The flavonoids it contains have been linked to a diverse
group of polyphenols, including ellagitanins, gallotan-
nins and ellegic acid.
PJ antioxidant activity was studied mainly with regard
to cardiovascular function among non HD patients. Dif-
ferent studies demonstrated the anti-atherogenicity
properties of PJ by its ability to lower serum angiotensin
converting enzyme (ACE) activity which resulted in sys-
tolic blood pressure reduction [13], decreased common
carotid artery intima-media thickness (IMT) [14] and at-
tenuation of the myocardial ischemia in patients who
had congestive heart disease [15]. Recently, studies sug-
gested that PJ consumption may be beneficial in popula-
tions at high risk to develop atherosclerosis and CVD
[16,17]. The antioxidative effects of PJ were more im-
pressive in diabetic patients than in healthy controls
[17], leading to the assumption that PJ may have benefi-
cial effect in patients exposed to oxidative stress (OS)
burden. Since HD patients are exposed to the most se-
vere systemic OS compared to other clinical states, PJ
intake in this high risk population may be more effective
than in other groups of patients. We have shown the
beneficial effects of consistent consumption over one
year's time of PJ on ‘non traditional’ CV risk factors,
such as OS and inflammation, and on clinical outcome
such as reduction in intima media thickness [18]. Fur-
thermore, we have demonstrated PJ's ability to reduce
the incidence of infections, which is the second most
common cause of morbidity and mortality of HD pa-
tients [18] However, the effect of PJ on ‘traditional’ risk
factors, such as hypertension and lipid profile has not
yet been studied among HD patients.
The present study aims to characterize for the first
time, the long term effects of PJ consumption by HD pa-
tients on hypertension, lipid profile and incidence of
CVD.Methods
Study population
One dialysis center at the Western Galilee Hospital,
Nahariya, Israel participated in the study. Eligible partici-
pants were chronic HD patients aged >18 years who
underwent 3 h HD sessions weekly using low-flux high
performance cellulose-triacetate [sureflux- 190G, NIPRO]
or polysulfone membranes [FX 10, Fresenius]. Exclusion
criteria included: HD treatment for less than 3 months,
simultaneous participation in other clinical trials, patient's
refusal or inability to give informed consent due to mental
or physical state, or pregnancy (actual or planned) during
study period. One hundred and forty-nine HD patients
were identified as eligible. Of these, 101 HD patients were
recruited (detailed information regarding the study popu-
lation was published in our previous paper [18]). Re-
cruited patients did not differ from eligible subjects in
demographic, dialysis and comorbidity characteristics
[18]. All individuals gave their written informed consent
to participate in the study. The study was approved by
the Institutional Ethics Committee at the study center
(Helsinki Committee approval no. 2008-06-06). The
study was registered in ClinicalTrials.gov registration,
Identifier number: NCT00727519.
Study design
The study was a double-blind, placebo-controlled, ran-
domized, clinical trial. Two groups of HD patients were
compared: one group (n = 66) received 0.7 mmol of poly-
phenols in the form of 100 cc of PJ (Naturafood) and the
other (n = 35) received a matching 100 cc placebo juice
three times a week during the first dialysis treatment hour,
for one year. Patients, medical and laboratory staff were
all blinded to patient’s group allocation. The smaller
randomization ratio of 2;1, with only a modest loss in stat-
istical power [19] was chosen due to ethical (a potential PJ
effect according to previous studies) and feasibility consid-
erations. The study sample size (n = 101), with a ratio of
2:1, PJ: Placebo, was calculated to have 80% power (p =
0.05) to detect 5% decrease in SBP (as demonstrated pre-
viously among hypertensive patients [13]), assuming a
mean SBP level of 140 ± 20 mm Hg according to our pre-
liminary results.
During the study period patients were instructed not
to drink any other fresh fruit juice at home. Verification
of juice intake was carried out by the study investigator
and was documented. Patients who did not drink the
juice at least 3 times were excluded from the study.
Blood for lipid profile measurements was drawn at 0, 3,
6 and 12 months of study intervention, always before
dialysis, from the arterial sampling port closest to the
patient. Three sequential blood pressure (BP) measure-
ments performed before dialysis initiation were used to
calculate the mean systolic and diastolic blood pressure
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tion. Pulse pressure (PP) was calculated by SBP minus
DBP.
PJ Juice
In order to choose the commercial PJ with the highest
polyphenols levels, several hand squeezed and different
commercial juices available in Israel were analyzed by the
colorimetric assay in Migal Galilee Technology Center, as
previously described [20,21]. PJ from Naturafood manu-
facturer [Turkey] was found to have the highest concen-
tration of polyphenols, each 100 cc of PJ contained
0.7 mmol of polyphenols, and was used in this study. The
juice was kept at room temperature <25°C until used.
Placebo Juice
The placebo was chosen to resemble the pomegranate
juice in color and taste and was prepared especially for
this study by food engineers. The placebo contained: pom-
egranate artificial extract of Frutarom Ltd; Citric acid;
Caramel as color material; Aspartame and Acesulfame as
sugar substitutes. Analyzing the placebo juice using colori-
metric assay verified that the juice has no polyphenols.
During placebo juice preparation, comparisons tests of fla-
vor between placebo juice and Pomegranate Juice were
performed by two independent testers to verify that pla-
cebo and Pomegranate Juice had a similar taste.
Outcomes
The primary endpoints were traditional CV risk factors
including: number of antihypertensive drugs taken at the
end of follow up compared to study initiation, mean
SBP, DBP and PP, as well as lipid profile (mean levels of
TG, HDL, LDL, total cholesterol).
Secondary outcome was incidence of CVD. CVD
events as a composite variable, consisted of hospitaliza-
tions due to acute myocardial infarction (MI) (fatal and
non fatal); ischemic stroke; new events of peripheral vas-
cular disease (excluding the arterio-venous fistula) and
unstable angina. Non fatal MI was defined as the pres-
ence of at least two of the following criteria: chest pain
of typical duration and intensity, and/or increased car-
diac enzymes and diagnostic electrocardiogram changes.
Fatal MI was defined as a death occurring within 24 h
from hospital admission. Death occurring outside hos-
pital for which no other cause was assigned was
regarded as sudden death and was included in the defin-
ition of CVD event.
Statistics
Data analysis was done with SPSS statistical analysis
software. Continuous data are reported as mean ± SD.
The t-test for independent samples, or Mann Whitney
test when appropriate, were used to detect differences incontinuous variables between treatment groups. Fre-
quency counts were calculated for categorical data. Dif-
ferences in these variables were assessed by Chi Square
Tests. In cases when expected values were lower than
necessary, Fisher Exact Test was used. In order to study
the time effect of PJ/Placebo on hypertention and lipid
profile, repeated measures and Bonferroni post hoc ana-
lyses were done separately in each of the groups. In order
to retain the intention to treat analysis we used the last
observation carried forward method for missing data.
Survival curve comparing the effect of treatment on
CVD events was calculated by the Kaplan-Meier method
using the intention-to-treat (ITT) principle.
All statistical tests were two-sided, and statistical sig-
nificance was defined as P < 0.05.
Results
Characteristics of study population
Characteristics of the 101 patients are described in our
previous paper [18]. Briefly, the two studied groups were
similar at study initiation in demographics, co-morbidities,
number of drugs and biochemical characteristics. The study
population's mean age was 66.5 ± 11.8 years and 54.5%
were males. Median follow-up time for the two groups was
12 months (range 0.25 – 12.6 months). The total dropout
rate was 33.7%, insignificantly higher among PJ group
(37.8%) as compared to the placebo group (25.7%). Patients
who withdrew from the study did not differ from those
who remained in their demographic, co-morbidy, treatment
and biochemical characteristics. Furthermore, in spite of
the 33.7% dropout rate, it should be noted that the base-
line characteristics of patients who survived until the
end of the study were similar at study initiation, indi-
cating retained randomization success. Adverse events
such as stomach upset or other GI-related effects were
not demonstrated.
Primary outcome
The distribution of the number of anti-hypertensive medi-
cations used at study entry was similar between the two
studied groups (mean 1.5 ± 1.2 drugs among PJ compared
to 1.1 ± 1.6 drugs among placebo group, p = 0.09). After
one year of intervention a significant (P = 0.01) change in
this distribution, as an ordinal variable (decrease, increase
and no change) was noticed between the two group. The
number of antihypertensive drugs decreased in 22.7% of
the PJ patients, compared to 8.6% in the placebo group,
while an increase was documented in 10.6% of the PJ pa-
tients compared to 31.4% in the placebo group (Figure 1).
As shown in Table 1, among patients for whom the num-
ber of antihypertensive drugs did not change (66.7%
(N = 44) and 60% (N = 21) of patients in the PJ and pla-
cebo group, respectively), treatment with PJ was associ-
ated with a significant time response reduction in SBP and
Figure 1 Changes in the number of anti HTN drugs after 12 months of intervention.
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duced after one year of intervention by 6.8% (Mean delta
9.8 mm Hg, P.V of paired T-test = 0.01), while pulse pres-
sure was reduced by 8.8% (Mean delta 6.6 mm Hg, P.V
of paired T-test = 0.004). No significant changes were
demonstrated among the placebo group. According toTable 1 SBP, DBP and PP during the study period by treatme
analysis, using last observation carried forward method for m
PJ
Time N Mean ± SE
(mm Hg)
P for trend
SBP† 0 44 145.6 ± 21.9 0.001
3 M 143.6 ± 23.9
6 M 141.7 ± 20.4
12 M 135.7 ± 21.3*
SBP≥ 140 at
study initiation
0 26 157.8 ± 12.9 <0.001
3 M 153.2 ± 18.8
6 M 149.5 ± 14.8**
12 M 144.0 ± 16.9*
DBP†† 0 44 70.9 ± 11.4 0.09
3 M 70.6 ± 12.3
6 M 69.6 ± 12.5
12 M 67.7 ± 13.8
PP††† 0 44 74.6 ± 19.5 0.04
3 M 72.9 ± 20.0
6 M 72.1 ± 17.0
12 M 68.0 ± 16.6***
*P < 0.05 for 12 m vs. 0 m and 3 m; **P < 0.05 for 6 m vs. zero time; ***P < 0.05 for
Mann-whitny U test; †Systolic blood pressure; ††Diastolic blood pressure; ††† PulseBonferroni test, the SBP at 12 months' intervention was
significantly lower than the level at study initiation and at
3 months' intervention.
Among patients with baseline SBP ≥140 mm Hg (N =
26 for PJ group, N = 5 for placebo group) the significant
effect of PJ consumption on blood pressure reductionnt group, repeated measures and Bonferroni post hoc
issing data
Placebo P***** for PJ vs.
placebo at zero
time and at 12 m
N Mean ± SE
(mm Hg)
P for trend
21 129.6 ± 27.2 0.15 0.28
131.2 ± 25.5
138.8 ± 24.8
135.6 ± 27.7 0.96
5 162.0 ± 10.6 0.42 0.54
157.1 ± 13.9
156.2 ± 17.6
157.8 ± 10.3 0.12
21 62.0 ± 15.7 0.46 0.09
64.5 ± 13.5
61.5 ± 16.5
63.8 ± 20.4 0.38
21 64.3 ± 16.1 0.02 0.24
66.5 ± 19.2
77.3 ± 14.5****
68.8 ± 14.2 0.84
12 m vs. zero time; ****P < 0.05 for 6 m vs. zero time; *****T-test or
pressure.
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more pronounced: SBP was reduced by 5.3% after 6 m,
and by 8.7% after 12 m of intervention (Table 1). No
changes were observed in DBP in both groups.
Among patients in the placebo group a significantly
increased PP was demonstrated. PJ consumption not
only attenuated this increase but also significantly de-
creased it (Table 1).
Normal values of LDL and total cholesterol were dem-
onstrated for the two study groups (Table 2). Treatment
with PJ was not associated with significant changes in
the above parameters. However, it was associated with
significant time response improvements in HDL and TG
levels, more evidently among patients with a pathologic
level of these parameters (Table 2). Among patients with
abnormal levels, following 12 months of intervention,
levels of HDL were significantly higher while levels of
TG significantly decreased among PJ patients as com-
pared to the placebo subjects (Table 2).Table 2 Lipid profile during the study period by treatment gr
analysis, using last observation carried forward method for m
PJ
N Mean ± SD P for tre
LDL mg/dl 0 66 95.1 ± 31.5 0.07
3 M 98.9 ± 35.6
6 M 95.4 ± 32.4
12 M 100.0 ± 33.1
Total cholesterol mg/dl 0 66 164.8 ± 37.1 0.27
3 M 167.7 ± 40.7
6 M 163.4 ± 38.9
12 M 167.3 ± 43.5
HDL mg/dl 0 66 33.1 ± 9.5* <0.001
3 M 37.2 ± 11.3
6 M 36.6 ± 10.9
12 M 36.8 ± 10.8
HDL ≤40 mg/dl
at study initiation
0 54 29.7 ± 5.7* <0.001
3 M 33.8 ± 7.8
6 M 33.6 ± 7.7
12 M 33.6 ± 7.5
TG mg/dl 0 66 183.6 ± 101.6** 0.05
3 M 175.7 ± 90.8
6 M 174.0 ± 89.8
12 M 167.3 ± 86.3
TG ≥200 mg/dl
at study initiation
0 20 310.1 ± 87.8** 0.02
3 M 267.3 ± 86.6
6 M 248.7 ± 100.5
12 M 237.4 ± 102.5
*P < 0.05 for zero time vs. 3, 6 and 12 m; **P < 0.05 for zero time vs. 6 m and 12 m;Secondary outcomes
CVD events
The CVD incidence rates by group allocation, rate ratios
and attributable risks are shown in Table 3. As seen, PJ
intake, as compared to Placebo intake, was associated
with 39% and 46% incidence rate reduction of the first
and second CVD events, respectively. In addition, the
reduction of the first event, as compared to the second
event, was more pronounced in the PJ group (5.4 times
lower incidence rate), as compared to the placebo group
(4.7 times lower rate). Due to a small number of events,
the difference between the two groups, as expressed by
the Kaplan-Meier survival analysis, did not reach statis-
tical significance (Figure 2).
Discussion
In the present study we demonstrated that intake of
polyphenols-rich commercial PJ with anti-atherogenicity
properties [13], improved the levels of SBP, PP, TG, andoup, repeated measures and Bonferroni post hoc
issing data
Placebo P*** for PJ vs.
placebo at 12 mnd N Mean ± SD P for trend
35 95.8 ± 28.9 0.38 0.85
98.0 ± 28.1
91.8 ± 25.1
94.3 ± 27.2 0.39
35 163.5 ± 33.4 0.18 0.86
171.7 ± 35.1
164.8 ± 38.0
165.1 ± 35.8 0.79
35 36.6 ± 10.7 0.18 0.10
37.0 ± 11.7
37.3 ± 12.9
34.3 ± 15.4 0.40
23 30.2 ± 5.6 0.09 0.84
31.2 ± 7.6
31.8 ± 10.2
27.6 ± 11.6 0.03
35 176.7 ± 86.7 0.04 0.73
192.9 ± 100.7
193.6 ± 90.5
206.1 ± 109.4 0.05
10 288.1 ± 71.9 0.15 0.13
318.2 ± 96.6
301.5 ± 78.2
320.4 ± 56.8 0.008
***T-test or Mann-whitny U test.
Table 3 Effect of PJ intake on the incidence rate, rate ratio and attributable risk of first and second CVD events
CV Events Group Incidence rate Rate ratio P.V (95% CI) Attribute risk
First event PJ 10648:24PM 1000 ¼ 15:42 1000PM= 0.61 0.30 (0.25-1.5) 25:03 1000PM−15:42 1000PM==
25:03
1000PM=
 100 ¼ 38:4%
Placebo 9359:57PM 1000 ¼ 25:03 1000PM=





 100 ¼ 46:3%
Placebo 2376:46PM 1000 ¼ 5:31 1000PM=
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able among patients with higher levels of SBP and TG
and among subjects with lower levels of HDL. PJ intake
was also found to be related to the decrease in the num-
ber of anti hypertensive drugs, highlighting its beneficial
effect on blood pressure level. It must be emphasized
that when comparing the two treatment groups HDL
and TG were the only parameters who demonstrated
significant differences, which might be explained for
both factors by an improvement in the PJ group and im-
pairment in the placebo group. Furthermore, PJ had no
demonstrable effect on total cholesterol and LDL levels,
probably due to their normal levels at study entry. Our
results are in agreement with studies conducted in other
chronic populations, demonstrating reduction in SBP
[13] and improvement in lipid profiles among patients
who consumed PJ [16]. Our study demonstrated for the
first time the anti-hypertensive and anti- hyperlipidemic
properties of PJ among HD patients.Figure 2 Kaplan-Meier survival curves following first CVD event.It is widely accepted that hypertension and dyslipidemia
are contributors to the atherosclerotic process, as well as
independent predictors of CVD in CKD and dialysis pa-
tients [1]. As such, our results in the current and previous
study [18] indicate the potentially important cardioprotec-
tive role of PJ. In spite of the above we did not succeed to
show a significant reduction in the incidence of CVD,
probably due to the longer intervention period needed to
demonstrate a statistically significant effect.
The mechanism by which PJ consumption reduced
SBP may relate to its ability to decrease ACE activity
(secondary to its antioxidant properties) or may be due
to a direct effect on serum ACE activity [13]. Further-
more, as reactive oxygen species (ROS) contribute to
endothelium dependent contraction and to increased
vascular resistance, the antioxidative effects by PJ, as we
previously demonstrated [18], can possibly restore endo-
thelial function and hence decrease blood pressure
[13,22]. SBP reduction may also be a result of PJ's ability
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and to enhance the nitric oxide synthase bioactivity [24].
In contrast to SBP reduction, the mechanism underlying
the anti- hyperlipidemic effect of PJ is unclear. Both an
inhibition of intestinal absorption, as well as accelerated
clearance of plasma triglycerides lipid may account
for the observed hypolipemic action of PJ [25]. The
beneficial effects of PJ on HDL and TGs could be medi-
ated by its ability to induce increment in paraoxonase 1
[26], protecting HDL from oxidation [27,28], and in par-
aoxonase 2 [29], influencing TG accumulation by mac-
rophages as well their TG synthesis [30].
Important questions related to interpretation of our
above results are whether the associations found are real
and causal. Taking into consideration the uncompromis-
ing methodology described, there is no reason to believe
that biases have been introduced. As for causality, all
Hill’s criteria were met: the clinical trial methodology as-
sured temporal relationship issues; the protective associ-
ations between PJ exposure and cardiovascular events
were found strong; our findings regarding the association
between polyphenols- rich juice and its anti-hypertensive
and hypolipemic properties were consistently described
across other studies of divergent designs and popula-
tions [13,16,25]; a time response relationship was dem-
onstrated between the intervention duration and
outcomes; and there is a possible biological explanation
for the relationships noticed between PJ intake and the
demonstrated results (described above). Nevertheless,
some methodological limitations should be mentioned:
first, this study was a small single center trial, which
may limit its external validity (generalizability); though
the sample size was adequate to examine all study as-
sumptions. In addition, data collection by one investigator
in one trial center assured high quality of data collected.
Second, there is no data regarding the pharmacokinetics
of polyphenols gastrointestinal absorption among HD pa-
tients. However, the effect on SBP and lipid profile was
demonstrated only among the PJ group, supporting the
notion of a PJ effect.
Conclusions
The significant beneficial effect of PJ intake on SBP, PP
and lipid profile among HD patients, in addition to its
beneficial effect on oxidative stress and inflammation,
suggests that constant PJ consumption can offer wide pro-
tection against cardiovascular events - the main cause of
morbidity and mortality among HD patients.
Furthermore, as controlled consumption of PJ has
been shown to lower morbidities in HD patients it is ex-
pected to reduce costs associated with those patients'
care. Further multi centered clinical studies are needed
to substantiate our findings that while directly improving
patients' quality of life, PJ can also significantly reducehealth expenditure. Such studies might well influence fu-
ture policy makers to include PJ as part of state-funded
standard care for HD patients.
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